Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-23T01:55:32.909Z Has data issue: false hasContentIssue false
  • English
  • Français

Relapse and recurrence prevention in major depression: a critical review of placebo-controlled efficacy studies with special emphasis on methodological issues

Published online by Cambridge University Press:  16 April 2020

J.G. Storosum ,
B.J. van Zwieten ,
H.D.B. Vermeulen ,
T. Wohlfarth  and
W. van den Brink
J.G. Storosum*
Affiliation:
Medicines Evaluation Board of the Netherlands Den Haagthe HagueThe Netherlands Psychiatric Department of the Academic Medical Centre University of Amsterdam, Tafelbergweg 25Amsterdam, 1105 BC Amsterdam The Netherlands
B.J. van Zwieten
Affiliation:
Medicines Evaluation Board of the Netherlands Den Haagthe HagueThe Netherlands
H.D.B. Vermeulen
Affiliation:
Psychiatric Department of the Academic Medical Centre University of Amsterdam, Tafelbergweg 25Amsterdam, 1105 BC Amsterdam The Netherlands
T. Wohlfarth
Affiliation:
Medicines Evaluation Board of the Netherlands Den Haagthe HagueThe Netherlands
W. van den Brink
Affiliation:
Medicines Evaluation Board of the Netherlands Den Haagthe HagueThe Netherlands
*
* Correspondence and reprints: E-mail address: [email protected] (J.G. Storosum).
Get access

Summary

This article critically reviews the design and methodology of studies aimed at evaluating relapse and recurrence prevention in major depression. A literature search in MEDLINE was performed with the medical subject headings ‘depression’, ‘recurrence’, ‘relapse’, ‘prevention’ and ‘study’. This search covered the period from January 1990 to July 1999. Only long-term placebo-controlled studies that included patients with non-chronic major depression were selected. Two types of design could be distinguished: randomised withdrawal studies in responders/remitters (N = 11) and extension studies in responders without re-randomisation (N = 3).

Randomised withdrawal studies are suitable for demonstrating long-term efficacy for the duration of the study period. However, this design does not permit a clear differentiation between relapse or recurrence and, therefore, is not suitable to demonstrate unequivocally relapse prevention or recurrence prevention. Extension studies in short-term responders without randomisation are not even suitable to demonstrate long-term efficacy.

A novel design is proposed that overcomes the weaknesses of designs employed thus far. In essence, this design calls for a long-term randomised placebo-controlled study in patients who are free of medication for a substantial period of time and who fulfil the criteria of major depression (recurrent) in sustained remission (e.g., HDRS < 7) as a possible option.

Keywords

long-term efficacymajor depressionmethodologyrecurrencerelapse
Type
Original Article
Information
European Psychiatry , Volume 16 , Issue 6 , September 2001 , pp. 327 - 335
Copyright
Copyright © 2001 Éditions scientifiques et médicales Elsevier SAS. All rights reserved

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Angst, JBaastrup, PGrof, PHippius, HPöldinger, WWeis, P.The course of monopolar depression and bipolar psychoses. Psychiatr Neurol Neurochir 1973; 76: 489–500.Google ScholarPubMed
Anton, SFRobinson, DSDouglas Roberts, DLKensler, TTEnglish, PA., et al. Long-term treatment of depression with nefazodone. Psychopharmacol Bull 1994; 3: 165–9.Google Scholar
Coryell, WAkiskal, HSLeon, ACWinokur, GMaser, JDMueller, TI., et al. The time course of nonchronic major depression. Arch Gen Psychiatry 1994; 51: 405–10.CrossRefGoogle Scholar
Doogan, DPCaillard, V.Sertraline in the prevention of depression. Br J Psychiatry 1992; 160: 217–22.CrossRefGoogle ScholarPubMed
Entsuah, ARRudolph, RLHacket, DMiska, S.Efficacy of venlafaxine and placebo during long-term treatment of depression: a pooled analysis of relapse rates. Int Clin Psychopharmacology 1996; 11: 137–45.Google ScholarPubMed
European Commission, Directorate-General III Industry. Clinical guidelines: medicinal products for treatment of depression. The rules governing medicinal products in the European union. Volume III, part 2. Eudra/G/96/010.Google Scholar
Feiger, ADBielski, RJBremer, JHeiser, JFTrivedi, MWilcox, X., et al. Double-blind placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression. Int Clin Psychopharmacology 1991; 14: 19–28.CrossRefGoogle Scholar
Ferreri, MColonna, LLeger, J-M.Efficacy of amineptine in the prevention of relapse in unipolar depression. Int Clin Psychopharmacology 1Suppl1997 39–45.CrossRefGoogle Scholar
Frank, EKupfer, DJCornes, CJarret, DBMallinger, AGThase, ME., et al. Three-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990; 47: 1093–9.CrossRefGoogle Scholar
Frank, EPrien, RFJarrett, RBKeller, MBKupfer, DJLavori, PW., et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Arch Gen Psychiatry 1991; 48: 851–5.CrossRefGoogle ScholarPubMed
Greenhouse, JBStangl, DKupfer, DJPrien, RF.Methodologic issues in maintenance therapy clinical trials. Arch Gen Psychiatry 1991; 48: 313–8.CrossRefGoogle ScholarPubMed
Keller, MBKlerman, GLLavori, PWCoryell, WEndicott, JTaylor, J.Long-term outcome of episodes of major depression: clinical and public health significance. JAMA 1984; 252: 788–92.CrossRefGoogle ScholarPubMed
Montgomery, SADunbar, G.Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacology 1993; 8: 189–95.CrossRefGoogle ScholarPubMed
Montgomery, SARasmussen, JGCTanghøj, P.A 24-week study of 20 mg citalopram 40 mg citalopram and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacology 1993; 8: 181–8.CrossRefGoogle ScholarPubMed
Montgomery, SAAngst, JBuller, RDerivan, AEvans, KFineberg, N., et al. Report of consensus meeting. Clinical relevance of response and improvement in psychopharmacology. A statement from the European College of Neuropsychopharmacology from an ECNP workshop October 1995. Eur Neuropsychopharmacol 1995; 5: 531–3.Google Scholar
Montgomery, SAReimitz, PEZivkov, M.Mirtazapine versus amitriptyline in the long-term treatment of depression; a double-blind placebo-controlled study. Int Clin Psychopharmacology 1998; 13: 63–73.CrossRefGoogle ScholarPubMed
Prien, RFKupfer, DJ.Continuation drug treatment for major depressive episodes: how long-should it be maintained?. Am J Psychiatry 1986; 143: 18–23.Google ScholarPubMed
Prien, RFCarpenter, LLKupfer, DJ.The definition and operational criteria for treatment outcome of major depressive disorder: a review of the current research literature. Arch Gen Psychiatry 1991; 48: 796–800.CrossRefGoogle ScholarPubMed
Reimherr, FWAmsterdam, JDQuitkin, FMRosenbaum, JFFava, MZalecka, J.Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am J Psychiatry 1998; 155: 1247–53.CrossRefGoogle ScholarPubMed
Rios, LPThase, MEHowland, RHFriedman, ESSimons, ADTu, XM.A prospective test of criteria for response remission relapse recovery and recurrence in depressed patients treated with cognitive behavior therapy. J Affect Disord 1997; 43: 131–42.CrossRefGoogle Scholar
Robert, PMontgomery, SA.Citalopram in doses of 20-60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Int Clin Psychopharmacology 1Suppl1995 29–35.CrossRefGoogle Scholar
Rouillon, FSerrurier, DMiller, HDGerard, M-J.Prophylactic efficacy of maprotiline on unipolar depression relapse. J Clin Psychiatry 199; 152: 423–31.Google Scholar
Storosum, JGZwieten van, BJBrink van den, WGersons, BPRBroekmans, AW.Increased suicidal risk no argument against placebo-controlled trials in major depression. Am J Psychiatry in press.Google Scholar
Terra, JLMontgomery, SA.Fluvoxamine prevents recurrence of depression: results of a long-term double-blind placebo-controlled study. Int Clin Psychopharmacology 1998; 13: 55–62.CrossRefGoogle ScholarPubMed
Thase, MESullivan, LR.Relapse and recurrence of depression. A practical approach for prevention. CNS Drugs 1995; 4: 261–77.CrossRefGoogle Scholar
Versiani, MMehilane, LGaszner, PArnaud-Castiglioni, R.Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J Clin Psychiatry 1999; 60: 400–6.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.